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Abstract 
Exosomes are 40- to 100-nm membrane-bound small vesicles that carry a great variety of cellular 
cargoes including proteins, DNA, messenger RNAs (mRNAs), and microRNAs (miRNAs). These 
nanovesicles are detected in various biological fluids such as serum, urine, saliva, and seminal fluids. 
Exosomes serve as key mediators in intercellular communication by facilitating the transfer and 
exchange of cellular components from cells to cells. They contain various pathogenic factors 
whereby their adverse effects have been implicated in multiple viral infections and cancers. 
Interestingly, accumulating evidences showed that exosomes derived from tumour viruses or 
oncoviruses, exacerbate virus-associated cancers by remodelling the tumour microenvironment. 
In this review, we summarize the contributing factors of Epstein-Barr virus (EBV) 
products-containing exosomes in viral pathogenesis and their potential implications in EBV-driven 
malignancies. Understanding the biological role of these exosomes in the disease would 
undoubtedly boost the development of a more comprehensive strategy to combat EBV-associated 
cancers and to better predict the therapeutic outcomes. Furthermore, we also highlight the 
potentials and challenges of EBV products-containing exosomes being employed as diagnostic 
markers and therapeutic targets for EBV-related cancers. Since these aspects are rather 
underexplored, we attempt to underline interesting areas that warrant further investigations in the 
future. 
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Introduction 
The current progress of therapy or therapeutics 
development against cancers is still not able to 
address the elevating cancer-related morbidity and 
mortality worldwide. Multiple challenges continue to 
exist in the development of anticancer drugs, which 
include the lack of suitable study models [1], as well 
as conundrums over drug toxicity [2], delivery [3], 
and bioavailability [4]. Accumulating evidences 
demonstrate that surrounding stromal cells such as 
tumour-infiltrating lymphocytes, fibroblasts, 
mesenchymal stem cells and macrophages/ 
monocytes in tumour regions may contribute to the 
failure of anticancer drug treatment [5,6]. Other 
pathogenic factors derived from tumour viruses (also 
known as oncoviruses) [7,8] and tumour-derived 
exosomes [9,10,11] may also help to establish a 
protumoural microenvironment by orchestrating 
multiple tumour-mediated signalling pathways hence 
complicating the anticancer treatment.  
Exosomes are small membrane bound vesicles 
that are secreted by cells. These extracellular vesicles 
(EVs) carry a wide range of molecules that have 
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implications in cell-to-cell communications, hence 
contributing to pathogenesis of various diseases and 
infections [9,10,11,12,13]. There are several types of 
EVs which are apoptotic bodies (500-2000nm), 
microvesicles (50-1000nm), and exosomes (30-100nm) 
which are usually differentiated by cellular origins 
but not size [14,15]. Due to the lack of distinctive 
vesicle-specific marker within the membrane-bound 
small vesicles, the term exosomes are often used 
interchangeably with small EVs [16]. Exosomes are 
defined as membrane-bound vesicles formed within 
multivesicular bodies (MVBs) or late endosomes 
which secreted from the cell [15]. Exosomes are 
formed through an endocytic pathway (Figure 1), 
endocytosed materials are delivered to early 
endosomes and they are either sent for degradation 
after fusion with lysosomes, or enter the secretory 
pathway via MVBs. The vesicles within MVBs are 
known as intraluminal vesicles (ILVs) and they are 
called exosomes following their release from the MVB 
upon fusion with plasma membrane to the milieu 
(Figure 1) [14,15]. 
The roles of exosomes in viral pathogenesis have 
been recently reviewed, including those in human 
immunodeficiency virus type I (HIV-I) [12,13], EBV 
[17,18], hepatitis C virus (HCV) [19,20], and human 
T-cell lymphotropic virus type I (HTLV-1) [21,22]. 
More importantly, some of these exosomes have been 
shown to aggravate the tumour development and 
dissemination [14,23]. For examples, exosomes from 
EBV-infected nasopharyngeal carcinoma (NPC) cells 
contain hypoxia-inducible factor-1a (HIF1a) and 
latent membrane protein-1 (LMP-1) that contribute to 
the tumour development and progression in NPC 
[23,24]. NPC-derived exosomes also play multiple 
roles in immune evasion in order to support and 
sustain the tumour growth [24,25]. On the other hand, 
the human papilloma virus (HPV)-associated 
exosomes have been shown to contain microRNAs 
that were associated with cervical cancer [26]. 
More than 90% of world’s population is infected 
with EBV and its contributions to various lympho- 
and epithelial-malignancies such as NPC, gastric 
carcinoma (GC), Burkitt lymphoma (BL), Hodgkin 
lymphoma (HL), and Non-Hodgkin lymphoma 
(NHL) are well-documented [27,28]. Exosomes have 
been shown to play important roles in the EBV 
infection and spreading [17,18]. However, little is 
known about the functions of EBV product-containing 
exosomes in the cancer development and progression 
that have been partly discussed in several reviews 
that focus on virus-derived exosomes [14,22,29,30]. In 
this review, we summarize the functions of exosomes 
in EBV pathogenesis and their contributions to several 
EBV-driven malignancies based on current findings, 
particularly on NPC. We also discuss the potentials of 
developing the anti-cancer therapy that target the 
EBV-associated exosomes and exosome-based 
biomarkers for diagnosis of EBV-related cancers. 
Moreover, we attempt to highlight the entailed 
challenges and limitations in the aforementioned 
endeavours. 
 
 
Figure 1. Schematic diagram showing the EBV-related pathogenic factors that contributes to cancer pathogenesis via exosomal pathway. 
Internal vesicles or multivesicular bodies (MVBs) are formed by the inward budding of cellular compartments. The cargo is packaged into intraluminal vesicle (ILVs) 
within MVBs. The MVBs contain a wide range of pathogenic factors depending on the producer cell. The MVBs either fuse with lysosomes to degrade MVB contents 
or fuse with cell membrane to release exosomes. The exosomes enter the recipient cell via caveolae-mediated endocytosis and the pathogenic contents are 
implicated in the EBV-associated cancer pathogenesis. 
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Exosomes in EBV infection and 
persistence 
Exosomes are known to transfer proteins, DNAs, 
mRNAs, and miRNAs from cells to cells to modulate 
diverse cellular processes [14,22]. In recent years, 
works on pathogenic role of oncogenic virus-derived 
exosomes have been mostly focused on the cancer 
pathogenesis [29,31]. In the case of EBV-associated 
exosomes, their role in EBV infection and persistence 
is surprisingly less understood. It is crucial to 
understand the biology of exosomes in the virus 
pathogenesis given that virus-derived exosomes are 
likely to contain various virus-related proteins/genes 
that modulate the viral infection which may in turn, 
contribute to the cancer development and/or 
progression later on. Of note, the exosome contents 
largely vary depending on the state of viral infection. 
There is a general notion that the EBV infection 
aggravates the local infection site, hence increasing 
the frequency of the occurrence of EBV-related 
malignancies [27,32,33]. As EBV-associated exosomes 
are majorly detected in the virally infected cells, they 
may possibly aid EBV in manipulating the 
surrounding tumour microenvironment to favour 
tumour growth and survival. This can be supported 
by the work of Ahmed et al. who reported that EBV 
could hijack the exosomal pathway for the purposes 
of virus egress and immune evasion [34]. Cumulative 
evidences also showed that EBV-associated exosomes 
specifically pack a variety of viral components (eg., 
LMP-1, LMP-2A, EBERs, viral RNAs, miRNAs, etc) 
which may promote the EBV infection 
[14,22,23,24,25,31]. The following subsection shall 
discuss the role of exosomes containing different EBV 
products in contributing to EBV infection and 
persistence. 
Role of latent membrane proteins 
(LMPs)-containing exosomes 
EBV latent infection, in general can be divided 
into three types (type I, II, and III). Latency type I is 
characterized by a high expression of Epstein-Barr 
virus nuclear antigen-1 (EBNA-1) which is usually 
seen in BL and GC. On the other hand, EBNA-1, 
LMP-1, and LMP-2 expressions are commonly seen in 
latency type II which occurs in the course of HL and 
NPC. In the case of latency type III, all latent 
proteins/antigens are expressed as commonly seen in 
acquired immune deficiency syndrome 
(AIDS)-related lymphomas and lymphoblastoid cell 
lines (LCLs) [27,32].  
EBV LMP-1 and LMP-2 have profound effects on 
both virus and cancer pathogenesis. LMP-1 is the 
major viral oncogene expressed in most 
EBV-associated cancers, which mainly fall under the 
categories of latency type II and III as mentioned 
above. LMP-1 can be detected in exosomes from 
EBV-infected cancer cells and is transferable from 
producer to recipient cells using exosomes as vehicles 
[23,31]. This oncoprotein may not be directly involved 
in the establishment of EBV infection, but it 
contributes significantly to the success of virus 
spreading by ensuring the high production of 
infectious virions [35]. Previously, 
immunohistochemical study on NPC tumour tissues 
have first demonstrated the positive correlation 
between protein levels of LMP-1 and exosomal 
marker CD63, suggesting that LMP-1 up-regulates the 
exosomal secretion during NPC progression [23]. 
Indeed, recent findings by Hurwitz et al. showed that 
both exosomal proteins’ level and extracellular vesicle 
secretion increased following LMP-1 expression. This 
resulted in greater LMP-1 accumulation and 
packaging in CD63-positive exosomes which can be 
impaired upon CD63 ablation [36]. Given the above 
considerations, it is likely that LMP-1 could also 
enhance EBV spreading by stimulating the production 
of pathogenic exosomes which include the exosomal 
LMP-1 as well.  
Work by Nanbo et al. on the other hand, showed 
that LMP-1-containing exosomes increased the 
expression of intercellular adhesion molecule 1 
(ICAM-1) that subsequently increased the 
proliferation rate of type III latency EBV-infected cells 
[37]. In contrast, exosomal LMP-1 derived from LCLs 
have been shown to inhibit the proliferation of 
peripheral blood mononuclear cells (PBMCs) [38]. 
Similarly, NPC-released exosomes containing LMP-1 
and galectin 9 also exhibit the intrinsic T-cell 
inhibitory activity [24]. These findings collectively 
suggest that exosomes containing LMP-1 can promote 
EBV pathogenesis mainly by down-regulating the 
antiviral immune responses whilst sustaining and 
supporting the growth of EBV-infected cells.  
Similar to LMP-1, presence of LMP-2A has also 
been detected in exosomes collected from 
EBV-infected LCLs [39]. Interestingly, it has been 
shown that cholesterol depletion via 
methyl-beta-cyclodextrin (MCD) treatment can 
elevate the exosomal LMP-2A level and stability [40]. 
However, the virus-specific effect of the 
exosome-derived LMP-2A in the EBV pathogenesis 
has not been evaluated before. Hence, little is known 
for the role of exosomal LMP-2A in virus 
pathogenesis as compared to the exosomal LMP-1. 
This question warrants future investigations as the 
pathogenic effects of cellular LMP-2A have been 
profoundly implicated in EBV infection [41, 42] and 
such effects could also be potentially manifested by 
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the exosome-derived LMP-2A. 
Role of EBV RNAs 
In addition to LMPs, EBV-associated exosomes 
could also contain the Epstein-Barr virus-encoded 
small RNAs (EBERs). EBERs (i.e., EBER-1 and EBER-2) 
are non-coding RNAs that are abundantly expressed 
through the exosomal secretion in EBV-infected cells 
[34,43]. These EBERs are mainly responsible for the 
cellular transformation and anti-viral innate 
immunity [44]. Ahmed and co-workers demonstrated 
that EBERs were excreted in the form of exosomes 
along with lupus antigen (La) ribonucleoprotein, 
which is an EBER-binding protein [34]. However, the 
pathogenic effects of EBER-carrying exosomes upon 
their internalization into the neighbouring cells 
remain unexplored, which requires further 
investigation.  
EBV exosomes may also contain other viral 
mRNAs and miRNAs that are known to mediate EBV 
pathogenesis and persistence [18,45,46]. For instances, 
exosomes derived from EBV-transformed LCL can 
transfer the mature EBV-encoded miRNAs to the 
recipient dendritic cells (DC) to suppress the 
expression of EBV target genes in the cells [45]. While 
the EBV-containing exosomes play significant roles in 
the viral pathogenesis, the mechanism mediating the 
internalization of these exosomes into the target cells 
is still unclear although it underlies the phenotypic 
modulation of target cells by the exosomes. Nanbo 
and co-worker demonstrated that the exosomes from 
EBV-uninfected, type I and type III latency 
EBV-infected cells internalized into the 
EBV-uninfected epithelial target cells via 
caveola-dependent endocytosis [37]. Since EBV 
products-containing exosomes could bind to various 
proteins/ receptors on target cells such as CD21 on B 
cells [47], exosome internalization is anticipated to be 
mediated via receptor-associated pathways. More 
studies are still required to decipher the exosome 
internalization pathway that facilitates EBV 
pathogenesis and persistence, which may contribute 
to EBV-associated carcinogenesis. 
EBV-Associated Exosomes in Tumorige-
nesis and Tumour Dissemination 
Tumour-derived exosomes have been known to 
aggravate the progression and invasion of various 
cancers including breast, ovarian, and brain cancers 
[14,22]. While the EBV-associated exosomes facilitate 
the EBV infection and spreading [35], there are 
evidences showing that these exosomes contribute to 
various EBV-associated cancers such as NPC, GC, and 
BL [23]. For instances, EBV oncoproteins LMP-1 
released from exosomes has been involved in the 
activation of several tumour-related signalling 
pathways (i.e., EGFR/PI3K and AKT/ERK), and 
consequently promote tumour development and 
progression [31]. In this section, we discuss the 
pathogenic role of EBV product-containing exosomes 
in various EBV-associated lymphoid and epithelial 
malignancies. Recent reports that show the 
exosomes-driven tumorigenesis and progression in 
the EBV-related cancers are summarized in Table 1.  
Exosomal LMPs in EBV-related cancers 
LMP-1 is expressed in EBV-associated cancers 
that display latency type II and III which include 
NPC, HL, and AIDS-related lymphoma. 
Exosome-derived LMP-1 mainly attenuates the 
immune response during the establishment of EBV 
infection in the target cells. The immunosuppressive 
roles of exosomal LMP-1 are evident as shown in 
several studies on EBV-associated cancers. 
LMP-1-containing exosomes derived from 
EBV-infected lymphoblastoid and NPC cells were 
found to inhibit the T-cell activation and proliferation 
via a mechanism that could be mediated by the critical 
inhibitory motif in the conserved transmembrane 
domain of LMP-1 [24,48]. Flanagan and co-workers 
also proposed that exosomes containing LMP-1 may 
block the activity of infiltrating T-cells upon uptake of 
these exosomes and this blockade may contribute to 
the immune evasion of tumour cells [38]. In another 
study, Ceccarelli and colleagues showed that the 
LMP- induced the expression and extracellular release 
via exosomes of fibroblasts growth factor 2 (FGF-2), a 
proangiogenic factor in tumour invasion. More 
remarkably, the authors also showed that LMP-1 
could accumulate and concentrate together with 
FGF-2 in multivesicular bodies prior to their exosomal 
release via the Na(+)/K(+)-ATPase-dependent 
pathway [49]. 
Meckes and co-workers on the other hand, 
showed that LMP-1-containing exosomes from 
LMP-1-overexpressed C666-1 NPC cells contained 
EGFR and PI3K as well. These exosomes were able to 
transfer LMP-1 and activate the ERK and AKT 
signalling pathways in multiple cell types, including 
fibroblast, uninfected epithelial, and HUVEC cells 
[31]. This finding suggests that the transfer of 
oncogenic LMP-1 may modulate the behaviour of 
surrounding stromal cells, causing their aberrant 
activation that favours primary tumour growth via 
enhanced vascularization as in the case example of 
HUVEC cells. It can be envisaged that neighbouring 
epithelial cells could be possibly transformed into 
cancer cells as a consequence of the oncogenic LMP-1 
transfer via the exosomal pathway. Apart from that, 
exosomal LMP-1 also up-regulated the expression of 
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ICAM-1 or CD54 [37] in which their elevated 
expressions have been found in various cancers 
including NPC [50], GC [51], and NHL [52]. 
Interestingly, Verweij et al have shown that LMP-1 can 
escape lysosomal degradation by first accumulating 
into endosomes, followed by exosomal secretion 
mediated by its interaction with the exosomal marker 
CD63 [53]. High correlation of LMP-1 and CD63 also 
suggested that the LMP-1 up-regulated the exosomal 
secretion which may promote the EBV-associated 
cancers. [23]. These observations may help to shed 
light on its constitutive oncogenic activities in various 
EBV-associated cancers [54]. 
Cumulative findings suggest that the exosomal 
LMP-1 may promote the growth and progression of 
EBV-associated cancers (Table 1). Numerous studies 
have shown that cellular LMP-1 play multiple roles in 
the EBV latent infection and tumorigenesis 
particularly via activation of c-Jun N terminal kinase 
(JNK) [55], NF-kappaB [56], p38[57], 
phosphatidylinositol 3 kinase (PI3K)/Akt [58], MAPK 
[59], and JAK/STAT [60] signalling. Our group also 
has reported that LMP-1 overexpression promoted 
the degradation of p53 tumour suppressor protein 
which intimates that p53 could be inactivated in NPC 
by LMP-1 despite being found to be rarely mutated in 
the disease [61,62]. It remains to be seen whether 
exosome-derived LMP-1 retains all the functions of 
the cell-derived LMP-1. Similarly, epidermal growth 
factor receptor (EGFR) which is a LMP-1-inducible 
tumour-promoting target protein [63], is also secreted 
by exosomes [31]. Following the exosomal delivery, 
the exosomal EGFR may contribute to the cancer 
pathogenesis. Notwithstanding all the above findings, 
the exact mechanisms of the LMP-1’s exosomal 
packaging, trafficking, internalization, and secretion 
are still not fully understood and these require future 
investigation. 
As for LMP-2A, it has been shown to integrate 
into the exosomes and is released into the recipient 
cells. Yet, the role of exosomal LMP-2A in 
carcinogenesis is underexplored despite the fact that 
cell-associated LMP-2A have been extensively studied 
for carcinogenesis [64,65,66,67,68]. The fact that the 
LMP-2A is expressed consistently in all 
EBV-associated NPCs as compared to the restrictive 
expression of LMP-1 may suggest the clinical 
significance of exosomal LMP2A [69]. Further 
investigation is warranted to examine the function of 
exosomal LMP-2A in the cancer development and 
progression.
 
Table 1. Evidences supporting the role of EBV-associated exosomes in tumour progression. 
Exosomal proteins Producer cell Recipient cell Cancer type Pathogenic or oncogenic effect of EBV-exosomes Reference 
LMP-1 and 
HIF1α 
LMP-1-NP69 and 
LMP--AdAH NPC cell 
lines 
NP69 and 
AdAH 
NPC -LMP-1 induces HIF1α expression 
-Induction of epithelial-mesenchymal transition 
(EMT) 
-Increase of cell migration and invasiveness 
23 
LMP-1 and 
Galectin 9 
C15 and C17 NPC 
xenograft tumour lines 
PBMC-derived T-cells NPC -Inhibition of peripheral blood T-cell proliferation  24 
LMP-1 and 
Galectin 9 
C15, C17, C666-1 NPC 
xenograft tumour lines 
and NPC patients 
PBMC-derived 
EBV-specific CD4+ 
T-cell clones 
NPC -Induction of EBV-specific CD4+ T-cell apoptosis 
 
86 
 
 
CCL20 C15 and C17 NPC 
xenograft tumour lines 
PBMC-derived T-cells 
 
NPC -CCL20 facilitated human Treg recruitment, 
expansion, and upregulated their suppressive 
functions 
-Promote conversion of CD4+CD25- T cells to Treg 
25 
LMP-1 and FGF-2 LMP-1/FGF2-AdAH 
NPC cell line 
 
 
HUVEC NPC -LMP-1 induces expression of angiogenic factor 
FGF-2 and exosomal secretion 
-Increase of cell proliferation in HUVEC 
49 
LMP-1 and 
ICAM-1 
Mutu-, Mutu I, Mutu III 
BL cell lines and LCL 
CNE-1, HONE-1, 
NU-GC-3, A549 
BL, NPC, GC, 
lung 
-LMP-1 induces expression of ICAM-1 
-Increase of cell proliferation in CNE-1 NPC cell line 
37 
LMP-1, EGFR and 
miRNAs 
C666, LMP-1-C666, 
C33A cell lines and C15 
NPC xenograft tumour 
line 
HUVEC, C33A, Rat-1 NPC -Transfer of BART miRNAs to HUVEC cells 
-LMP-1 induces expression of EGFR 
-Activation of ERK and PI3K/Akt signalling 
pathways 
 
31 
BHRF1-3 miRNAs LCL MoDC and HeLa Not specific -EBV BART and BHRF1-3 miRNAs are transferred 
between B-cell and non-B cells 
-EBV BHRF1-3 miRNAs suppress CXCL11 
expression 
45 
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Exosomal RNAs in EBV-related cancers 
miRNAs are small non-coding RNAs with size of 
about 20 nucleotides that regulate various cellular 
processes [70,71]. The mature miRNAs interact with 
the target mRNAs and block their activities by 
repressing the translation. The effects of miRNAs 
have been implicated in EBV-associated cancers such 
as NPC [72,73,74], GC [68,75,76], and BL [77,78]. 
Pandya and colleagues have in fact shown that viral 
miRNA expression is consistently higher in cancerous 
tissues as compared to the adjacent non-cancerous 
counterparts in various solid malignancies [79]. It was 
also shown that the expression of these viral miRNAs 
is linked to significantly worse clinical outcome 
among early stage cancer patients, which potentially 
indicates the potential devastating pathogenic roles of 
viral miRNAs in cancer [79]. The tumour-promoting 
miRNAs are also detected in exosomes. Due to the 
exosome biogenesis, it is thought that the biological 
effects of exosome-derived miRNAs may be slightly 
different compared to the cell-derived miRNAs. 
However, cumulative findings suggest that exosomal 
miRNAs retains their tumorigenic effects in various 
cancers similar to the cell-derived miRNAs 
[80,81,82,83,84]. For instance, Melo and colleagues 
demonstrated that breast cancer cells secreted 
exosomes containing RNA induced silencing complex 
(RISC) proteins, Dicer, TAR RNA binding protein 
(TRBP), and Argonaute 2 (AGO2), and these 
exosomes are capable of processing the precursor 
miRNAs into the active miRNAs that induce tumour 
formation [80]. Interestingly, Ye and co-workers also 
demonstrated that exosomal miRNAs promoted the 
tumour progression in NPC [82]. However, the profile 
of miRNA-containing exosomes and the pathogenesis 
mechanism of the NPC-derived exosomes were not 
evaluated in this study. On the other hand, Choi and 
co-workers showed that miR-BART15-3p could be 
detected in the EBV-associated exosomes and its 
expression level was 2 to 16-fold higher in the 
exosomes compared to the cellular level [85], but its 
roles in tumorigenesis was again, not studied. 
Overall, current findings suggest that EBV miRNAs 
may have high tumorigenic activities but more 
studies need to be carried out to support this 
speculation.  
Similarly, EBV-associated exosomes have been 
shown to carry mRNAs encoding for EBV oncogenes 
such as LMP-1, LMP-2, EBNA-1, and EBNA-2 and 
small RNA EBERs [18,34] (Figure 1). In regards to 
cellular EBERs, our group has previously 
demonstrated that NPC cells stably expressing 
EBER-1 and -2 consistently displayed an increased 
growth rate [86]. Despite the potential oncogenic 
properties of exosomal EBV-encoded mRNAs, 
whether or not these mRNAs are transferable to 
recipient cells and exert the tumorigenic effects in 
EBV-associated cancers remains to be shown.  
Other exosomal proteins in EBV-related 
cancers  
In addition to LMPs, EBERs, EBV-related 
miRNAs and mRNAs, exosomes containing other 
pathogenic proteins have also been reported to 
promote EBV-related cancers such as the transcription 
factor Galectin-9 [24,87], Deoxyuridine triphosphatase 
(dUTPase) [88], EGFR [31,89], HIF1α [23], and other 
interleukins [90] (Figure 1). Keryer-Bibens and 
colleagues demonstrated that the EBV-infected 
NPC-derived xenograft cells, C15 and C17 released 
the galectin-9-containing exosomes which have 
inhibitory action against PBMC-derived T cell 
proliferation [24]. Similarly, high expression of 
exosomal galectin-9 was also detected in plasma from 
NPC patients and NPC-tumour xenografted mice and 
these exosomes induced apoptosis in the EBV-specific 
CD4+ T cells in the galectin-9-dependent manner [87]. 
In the case of dUTPase, an increased amount of this 
protein has been detected in exosomes derived from 
the EBV-positive BL cell line, Raji which are found to 
induce the cytokine release from DCs and PBMCs 
which may activate the NF-kappaB pathway [88]. 
Interestingly, EBV-associated exosomes also carry 
hypoxia-inducible factor-1α (HIF1α), a 
pro-tumorigenic molecule [23]. Aga and coworkers 
have shown that LMP-1-inducible exosomal HIF1α 
contributed to the epithelial-mesenchymal transition 
(EMT) that may suggest its pro-metastatic role in 
promoting cancer progression. As one of the 
important therapeutic target for anti-cancer therapy, 
EGFRs are also over-expressed in NPC-derived 
exosomes [31]. The same group have shown that the 
exosomal EGFR expression correlates with the LMP-1 
level and could be induced by LMP-1. More 
importantly, the exosomes derived from the Raji cells 
and other EBV-infected cell lines are enriched with 
various immune modulators such as 
interferon-inducible protein 16 (IFI16), cleaved 
caspase-1, IL-1β, IL-18, and IL-33 [90]. The presence of 
these proteins in the exosomes may suggest that the 
EBV utilize the host exosomal pathway in immune 
escape hence contributing to the progression and 
maintenance EBV-associated cancers.  
Targeting EBV-associated Exosomes for 
Diagnostics and Anti-Cancer Therapy  
As described in earlier sections, cumulative 
findings have shown the marked tumorigenic role of 
exosomes in EBV-associated cancers. This suggests 
that these exosomes potentially represent useful 
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biomarkers and strategies targeting these exosomes 
may be developed as a potent anti-cancer therapy. 
Similarly, EBV-associated exosomes that contain 
several other pathogenic proteins can also be targeted 
for cancer biomarker and therapy development 
(Figure 2). In this section, we summarize findings 
from the current works exploiting the EBV-associated 
exosomes as diagnostic markers as well as for the 
development of anti-cancer therapy. We also attempt 
to highlight the potential challenges and limitations 
that may be encountered in the above efforts.  
 
 
Figure 2. Target proteins in EBV-associated exosomes for cancer 
diagnostics and anti-cancer therapies. LMP-2A, BARF1, and HIF1α have 
been previously targeted for cancer diagnostics while VEGF and galectin-9 are 
targeted for anti-cancer therapy development. Other proteins such as LMP-1, 
EGFR, EBV DNA, mRNAs, and miRNAs are being targeted simultaneously for 
both diagnostics and therapeutic purposes. 
 
EBV-associated exosomes as cancer diagnostic 
marker 
As abovementioned, exosomes containing 
EBV-related or other pathogenic factors may 
contribute to the cancer development and 
progression. These factors can potentially serve as 
useful markers for diagnosis or prognosis in cancers, 
particularly in the EBV-associated cancers. Recent 
advances in methods have facilitated the isolation of 
exosomes from the biofluids, making it a more 
feasible approach for the development of 
non-invasive liquid biopsy-based diagnostics [27,91]. 
The potential of developing exosomes into the 
biomarkers for cancers have been recently reviewed 
[92,93,94,95]. There have also been evidences 
suggesting that the EBV-associated oncoproteins can 
be targeted for cancer diagnosis. For instance, Houali 
and colleagues showed that both EBV oncoproteins 
LMP-1 and BARF1 could be detected in serum and 
saliva of NPC patients, and the secreted LMP-1 were 
strongly associated with the exosome-like vesicles 
[96]. The fact that the exosomes are abundantly 
expressed in patient serum and saliva [12] further 
support the potential of targeting the 
oncoprotein-enriched exosomes in cancer diagnosis. 
Mao and coworkers also highlighted the potential of 
LMP-1 and LMP-2A as the candidate biomarkers for 
diagnosis and prognosis of patients with NK/T-cell 
lymphoma [97]. In addition to EBV-related proteins, 
other pathogenic factors that are enriched in 
exosomes as abovementioned such as EBV DNA 
[98,99], EBV mRNAs [100,101], EBV miRNAs 
[102,103], Galectin-9 [87,104] have also been shown to 
be potential biomarkers for cancer diagnosis. On the 
other hands, the diagnostic value of EGFR and HIF1α 
has been previously demonstrated in other cancer 
types [105, 106]. More poignantly, exosomes have 
been shown to protect their cargoes from degradation. 
For instance, the encapsulated mRNAs and miRNAs 
are being protected from RNAses [107]. The stability 
of the exosomal contents therefore, makes them the 
attractive biomarker candidates for cancer diagnosis. 
Further investigations are needed to evaluate the 
sensitivity and specificity of exosome-containing 
pathogenic proteins to be used as potential 
biomarkers for cancer diagnosis particularly in 
EBV-associated cancers.  
EBV-associated exosomes as anticancer target 
It has been reported that the tumour-derived 
exosomes could be the one of the major reasons for the 
treatment failure in cancers [108,109]. In this regard, 
cancer progression could be inhibited by blocking the 
activities of these exosomes. Figure 1 summarizes the 
pathogenic and tumorigenic factors derived from the 
EBV-associated exosomes and the potential targets for 
anti-cancer therapy development. Indeed, 
EBV-related proteins and nucleic acids (eg., DNA, 
mRNA and miRNA) have been previously shown as 
potential promising targets for anti-cancer therapy 
development [110,111,112,113]. For instance, various 
strategies such as cell-based immunotherapy, 
antibody-based and drug-based therapies have been 
developed against EBV LMPs [111]. Cao and 
co-workers showed that DNAzyme resulted in 
significant tumour regression by targeting and 
cleaving off the LMP- mRNA from NPC patients [110]. 
Other tumour-promoting non-EBV proteins that 
could be targeted include EGFR [114,115] and VEGF 
[116,117]. Similarly, targeting tumour-derived 
exosomes has been earmarked as a potent therapeutic 
strategy for cancer therapy although it must be noted 
that its potential remains to be explored [109,118].  
In addition to carrying pathogenic factors that 
promote tumour formation and progression, 
tumour-derived exosomes could also play key roles in 
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immune evasion of cancer cells as mentioned above 
[24,25,34,38]. Hence, blocking these exosomes may 
restore the activity of functional immune cells to kill 
the cancer cells. The immunosuppressive activity of 
NPC cell-derived and patient plasma-derived 
exosomes has been demonstrated on the 
PBMC-derived CD4+ T lymphocytes. The 
galectin-9-containing exosomes have inhibited the 
EBV-specific T-cell proliferation and induced 
apoptosis, hence preventing the cancer cells from 
T-cell-mediated recognition and killing of cancer cells 
[24,87]. Development of a therapeutic strategy to 
block the galectin-9 or other proteins from the 
exosomes may therefore restore the normal immune 
surveillance. Over the past few years, considerable 
work has also been done on targeting the whole 
exosomes rather than targeting the specific proteins 
[119,120]. The exosomal removal using a modified 
kidney dialysis system has also been proposed to be 
introduced in the clinical settings [119]. These 
findings suggest that diminishing or eliminating the 
tumorigenic exosomes may be a good therapeutic 
approach to reverse the exosome-mediated cancer 
progression, particularly in the aspect of immune 
dysregulation.  
In addition to serving as therapeutic targets, 
exosomes have been interestingly adopted as vehicles 
for therapeutics delivery [121,122,123]. Ohno and 
coworkers demonstrated that the Let-7a 
miRNA-loaded exosomes targeting EGFR could be 
efficiently delivered to target the breast 
cancer-derived murine xenograft tissues [121]. 
Similarly, Qi and coworkers showed that 
exosome-based delivery of drug in murine hepatoma 
xenografts could cause significant regression of 
tumour size [122]. Hence, loading the existing 
exosomes with anti-EBV or anti-cancer therapeutic 
drugs or compounds might be a potent strategy to 
inhibit the tumour formation in addition to other 
advantages such as increasing the drug stability/ 
bioavailability and improving the drug delivery and 
cell permeation. Further investigations are warranted 
to examine the potency of these anti-EBV and/or 
anti-cancer exosomes in therapeutic intervention. 
Potential challenges and limitations 
While several lines of evidences showed that the 
EBV-containing exosomes can be targeted for the 
development of biomarker and/or anti-cancer 
therapy (Figure 2), several considerations need to be 
taken into account to ensure the success of the therapy 
and biomarker development. Sensitivity and 
specificity are important criteria for the cancer 
biomarker development. While the exosome- 
containing EBV oncogenic contents (eg. EBNAs, 
LMPs, and EBERs) have tumour-promoting and 
pathogenic properties and are expressed during the 
disease, they are not cancer type-specific and could be 
detected in various EBV-associated cancers such as 
NPC, GC, and BL [27]. Hence, other non-invasive tests 
such as cancer antigen screening and magnetic 
resonance imaging (MRI) are required in combination 
with potential exosomal analysis to enhance the 
specificity of diagnosis towards a particular cancer 
type. Furthermore, the expression of latent proteins 
LMPs such as LMP1 may be low or even at 
undetectable level especially during the early stage of 
tumour formation [124], hence the resultant 
sensitivity may be a potential issue. Comparatively, 
EBERs are more suitable targets for detection as they 
are consistently expressed at detectable amount in all 
EBV latently infected cells or tissues [44]. 
As an important therapeutic target, EBV 
proteins/nucleic acids can be targeted for tumour 
regression. There are a few challenges that may be 
encountered during the development of anti-cancer 
therapies. The exosomes play important roles in 
cell-cell communication mainly by regulating cellular 
processes, hence complete removal of exosomes is not 
a feasible therapeutic strategy as it will affect the 
well-being of cellular processes under a normal 
condition [30]. Hence, it is important to specifically 
target only the exosomes enriched with the 
pathogenic factors without affecting the biological 
activities of other existing exosomes. In addition, the 
exosomal contents may largely vary and 
heterogeneous depending on the sources or origins 
[12]. This may be another challenge especially the 
targeted exosomes are from the patient’s circulating 
blood. Furthermore, some potential targets may be 
scarcely expressed or not at all in the targeted 
exosomes which will lead to the treatment failure. 
Other considerations in exploiting exosomes for drug 
delivery include the dosage of exosome-targeting 
drugs that may vary from one to another, the delivery 
system for targeting exosomes, the stability of the 
delivered therapeutic molecules, and the treatment 
course. Further works are needed to evaluate the 
clinical safety of exosome-targeting treatment 
strategy. 
Conclusions  
EBV-associated exosomes undoubtedly play 
pivotal roles in the pathogenesis of the viral infections 
and EBV-associated cancers especially in NPC. The 
cumulative findings suggest that the EBV-associated 
exosomes are ideal targets for the development of 
diagnostic biomarker and anticancer therapy. 
However, several issues need to be taken into account 
during the development as abovementioned. Since 
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limited studies have been carried out in general, 
future investigations are warranted to evaluate the 
association of EBV-exosomes in other related cancers 
such as GC, BL, and NHL. The targeted exosomes 
could also be potentially developed into vaccines for 
EBV infections, hence diminishing the chances of 
developing the EBV-associated cancers. To our best 
understanding, this is the first review that discusses 
the role of pathogenic exosomes in contributing to 
EBV infection and the associated cancers in a much 
focused approach. 
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